A virtual form exploration, not a prediction of treatment results.
01 / MATERIAL
What is within.
Look into the material.
An HA gel composed of cross-linked hyaluronic acid and lidocaine hydrochloride. Discover the material through its light-catching texture.
HYALURONIC ACID / TEXTURE 01
↔ Drag to explore three gel textures
CROSS-LINKED HA24mg/mL
Cross-linked hyaluronic acid
LIDOCAINE HCl0.3%
Lidocaine hydrochloride
SYRINGE VOLUME1.1mL
Syringe volume
Supplied gel texture photographs; not test-result images.
02 / STRUCTURE & PERFORMANCE
From structure to performance.
Explore processes and reported test values from the manufacturer’s technical materials.
HBCT / MICROSTRUCTURE
Structure by design.
Microstructure, beginning with low-temperature crosslinking.
The manufacturer describes the three-dimensional HA gel microstructure through its HBCT low-temperature crosslinking process.
SAMPLE AHBCT HA
Original SEM images. Magnification, preparation and replicate details were not supplied. Images alone do not quantify clinical superiority.
RHEOLOGY / G′
Storage modulus G′
Ranges by manufacturer formulation
Fine60–120Pa
0150300 Pa
Drag or select a formulation
Bars show reported ranges, not means or error bars. Temperature, frequency, strain and replicate details were not supplied.
MGT / EXTRUSION
Consistency in motion.
13.62N
Manufacturer’s Deep formulation · 27G needle · average extrusion force
MGT is a micro-grinding process for consistent gel processing. The displayed value is the mean reported in the manufacturer’s test.
COHESIVENESS
Held together.
Cohesiveness test · lengths shown in the source
Fine2.4cm
Deep2.1cm
Volume2.0cm
Test speed, temperature and replicate details were not supplied. Lengths are not a ranking of clinical performance.
03 / PURITY
Purity, measured.
Explore raw-material criteria separately from final-product test results.
RAW MATERIAL
HA raw-material criteria
Endotoxin
≤ 0.020 IU/mg
Microbial contamination
≤ 5 CFU/g
FINAL PRODUCT
Final-product test table
Residual BDDE
0 ppm / reported
Heavy metals
< 1.0 ppm / reported
PURIFICATION02
Two stages · two weeks
Manufacturer’s technical data. 0 ppm is a reported result, not proof of absolute absence; the detection limit was not supplied.
04 / PRECLINICAL OBSERVATION
Observed over time.
Original animal-study MRI of a low-elasticity formulation. Select an observation interval.
MRI / OBSERVATION SERIES
0 weeks1 weeks2 weeks3 weeks
4 weeks8 weeks16 weeks24 weeks
KBIOHealth Animal Center · 2020.09.18–2021.03.23. These are observation times, not evidence of human longevity, retention or safety.
05 / THE COLLECTION
The collection, at a glance.
Product specifications
Ep. Alpha
Ep. Beta
Ep. Gamma
Cross-linked hyaluronic acid
24 mg/mL
24 mg/mL
24 mg/mL
Lidocaine hydrochloride
3 mg/mL (0.3%)
3 mg/mL (0.3%)
3 mg/mL (0.3%)
Syringe volume
1.1 mL
1.1 mL
1.1 mL
Needle
30G × 2
27G × 1
25G × 1
Cannula
—
25G × 1
23G × 1
Based on Aestyve carton labels. Store at 2–25°C, away from light and moisture. Refer to the latest label and instructions for expiry, lot and use information.
Materials and sources
Composition, volume and accessories: Aestyve packaging (P01). Process and test data: manufacturer technical materials dated 2026.01.26, pp.4–6, 9 (T01), and English manufacturer brochure p.1 (T02). Content follows the 2026 HA Collection catalog worksheet. Fine, Deep and Volume are manufacturer formulation names; these are not presented as Aestyve clinical outcomes.
